Discover
WGS
GeneDx Holdings Corp.
61.65
1 x 61.00
3 x 62.73
bid
ask
+
1.00
1.65%
undefined @ 04:00 PM
60.82 -0.83 (1.34%)
| Ytd | -52.60% | |
| 1y | -21.31% |
58.14
day range
61.99
32.21
52 week range
170.87
| Open | 59.52 | Prev Close | 60.65 | Low | 58.14 | High | 61.99 | Mkt Cap | 1.83B |
| Vol | 569.24K | Avg Vol | 1.33M | EPS | 0.85 | P/E | 72.53 | Forward P/E | 204.08 |
| Beta | 1.90 | Short Ratio | 5.22 | Inst. Own | 115.25% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 07-28 | 50-d Avg | 56.34 | 200-d Avg | 93.35 | 1yr Est | 78.44 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2026-08-03 | 2026-06 | -0.19 | N/A | N/A | N/A |
| 2026-05-04 | 2026-03 | -0.06 | -0.28 | -0.22 | -366.67% |
| 2026-02-23 | 2025-12 | 0.11 | 0.14 | 0.03 | 27.27% |
| 2025-10-28 | 2025-09 | 0.28 | 0.49 | 0.21 | 75.00% |
| 2025-07-29 | 2025-06 | 0.1 | 0.5 | 0.4 | 400.00% |
| 2025-04-30 | 2025-03 | 0.11 | 0.28 | 0.17 | 154.55% |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2026-06-29 | Guggenheim | Upgrade | Buy | Buy |
| 2026-06-23 | Piper Sandler | Upgrade | Overweight | Overweight |
| 2026-05-05 | Canaccord Genuity | Upgrade | Buy | Buy |
| 2026-05-05 | Wells Fargo | Upgrade | Overweight | Overweight |
| 2026-05-05 | Guggenheim | Upgrade | Buy | Buy |
| 2026-05-05 | BTIG | Upgrade | Buy | Buy |
Profile
GeneDx Holdings Corp., a genomics company, provides genetic testing services. The company primarily offers pediatric and rare disease diagnostics with a focus on whole exome and genome sequencing, as well as data and information services. It also develops an AI-based platform for next generation sequencing analysis, interpretation, and clinical reporting for rare disease, hereditary risk, and cancer testing. GeneDx Holdings Corp. was founded in 2000 and is headquartered in Stamford, Connecticut.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2026-06-04 | CASDIN CAPITAL, LLC | Beneficial Owner of more than 10% of a Class of Security | 0.00 | Purchase |
| 2026-06-17 | CASDIN ELI | Director and Beneficial Owner of more than 10% of a Class of Security | 4.08M | Conversion of Exercise of derivative security |
| 2026-06-15 | FEELEY KEVIN | Chief Financial Officer | 39.95K | Sale |
| 2024-11-17 | ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI | Beneficial Owner of more than 10% of a Class of Security | 2.72M | Sale |
| 2026-06-17 | MEISTER KEITH A | Director and Beneficial Owner of more than 10% of a Class of Security | 5.14M | Conversion of Exercise of derivative security |
| 2024-08-18 | OPKO HEALTH, INC. | Beneficial Owner of more than 10% of a Class of Security | 2.65M | Sale |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-03-30 | Corvex Management LP | 3.23M | 0.00 | 10.87% |
| 2026-03-30 | Casdin Capital, LLC | 3.01M | 0.00 | 10.13% |
| 2026-03-30 | BlackRock Inc | 1.55M | 0.00 | 5.22% |
| 2026-03-30 | Westfield Capital Management Company, L.P. | 1.37M | 0.00 | 4.61% |
| 2026-03-30 | The Goldman Sachs Group Inc | 1.33M | 0.00 | 4.50% |
| 2026-03-30 | ARK Investment Management LLC | 1.32M | 0.00 | 4.46% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2026-05-30 | ARK Innovation ETF | 1.06M | 0.00 | 3.59% |
| 2026-03-30 | ARK Disruptive Innovation Full Composite | 822.42K | 0.00 | 2.77% |
| 2026-04-29 | Vanguard Total Stock Mkt Idx Inv | 599.47K | 0.00 | 2.02% |
| 2026-03-30 | American Funds SMALLCAP World A | 459.49K | 0.00 | 1.55% |
| 2026-05-28 | iShares Russell 2000 ETF | 458.08K | 0.00 | 1.54% |
| 2026-05-30 | ARK Genomic Revolution ETF | 418.21K | 0.00 | 1.41% |
Split
| Split | Date |
|---|---|
| 1 : 33 | 2023-05-04 |